Tabula Rasa HealthCare Inc (TRHC) Given Average Recommendation of “Buy” by Analysts

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) has been assigned an average recommendation of “Buy” from the eleven research firms that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $27.86.

Several research firms recently issued reports on TRHC. Zacks Investment Research cut Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. BidaskClub cut Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. First Analysis began coverage on Tabula Rasa HealthCare in a research note on Wednesday, November 1st. They issued an “overweight” rating and a $41.00 target price on the stock. William Blair began coverage on Tabula Rasa HealthCare in a research note on Monday. They issued an “outperform” rating on the stock. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $35.00 target price on shares of Tabula Rasa HealthCare in a research note on Tuesday, November 7th. They noted that the move was a valuation call.

In other Tabula Rasa HealthCare news, major shareholder Growth Fund 1Q Lp Originate sold 684,180 shares of the firm’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $25.85, for a total value of $17,686,053.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce Luehrs sold 269,000 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $25.85, for a total transaction of $6,953,650.00. The disclosure for this sale can be found here. Insiders sold 1,107,180 shares of company stock worth $28,612,003 over the last three months. 45.80% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of TRHC. Bank of New York Mellon Corp purchased a new stake in Tabula Rasa HealthCare in the first quarter worth about $178,000. TIAA CREF Investment Management LLC lifted its holdings in Tabula Rasa HealthCare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock worth $110,000 after buying an additional 4,232 shares during the period. Russell Investments Group Ltd. lifted its holdings in Tabula Rasa HealthCare by 58.1% in the second quarter. Russell Investments Group Ltd. now owns 94,089 shares of the company’s stock worth $1,415,000 after buying an additional 34,565 shares during the period. Boston Partners lifted its holdings in Tabula Rasa HealthCare by 17.1% in the second quarter. Boston Partners now owns 235,180 shares of the company’s stock worth $3,540,000 after buying an additional 34,360 shares during the period. Finally, Cadence Capital Management LLC purchased a new stake in Tabula Rasa HealthCare in the second quarter worth about $210,000. Institutional investors and hedge funds own 31.85% of the company’s stock.

Shares of Tabula Rasa HealthCare (NASDAQ TRHC) traded down $0.73 during trading hours on Thursday, hitting $27.86. The stock had a trading volume of 241,945 shares, compared to its average volume of 106,561. Tabula Rasa HealthCare has a 52-week low of $11.59 and a 52-week high of $36.80. The company has a current ratio of 0.73, a quick ratio of 0.66 and a debt-to-equity ratio of 0.47.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.02. The firm had revenue of $33.27 million for the quarter, compared to analysts’ expectations of $31.76 million. Tabula Rasa HealthCare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period last year, the firm earned $0.06 earnings per share. analysts anticipate that Tabula Rasa HealthCare will post 0.05 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Tabula Rasa HealthCare Inc (TRHC) Given Average Recommendation of “Buy” by Analysts” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://sportsperspectives.com/2017/12/12/tabula-rasa-healthcare-inc-trhc-given-average-recommendation-of-buy-by-analysts.html.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply